Experiment 67058
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | WILT,TJ: MACDONALD,R: ISHANI,A:. (1999). BETA-SITOSTEROL FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW.. 83(9) |
| Amount utilized | |
| Compound isolated | |
| Disease | TO CONDUCT A SYSTEMATIC REVIEW OF THE EVIDENCE FOR THE EFFICACY OF BETA-SITOSTEROL IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA(BPH). FOUR TRIALS COMPRISING A TOTAL OF 519 MEN MET THE INCLUSION CRITERIA. ALL WERE DOUBLE-BLIND AND LASTED 4-26 WKS. THREE STUDIES USED NONGLUCOSIDIC BETA-SITOSTEROLS AND ONE USED A PREPARATION THAT CONTAINED ONLY BETA-SITOSTEROL-BETA-D-GLUCOSIDE. COMPARED WITH PLACEBO, BETA-SITOSTEROL IMPROVED URINARY SYMPTOM SCORES AND FLOW MEASURES. FOR THE TWO STUDIES REPORTING THE INTERNATIONAL PROSTATE SYMPTOM SCORE(IPSS). THE WEIGHTED MEAN DIFFERENCE(WMD) AGAINST PLACEBO WAS -4.9 IPSS POINTS. THE WMD FOR PEAK URINARY FLOW RATE WAS 3.91 ML/S(95% CI 0.91 TO 6.90, FOUR STUDIES) AND FOR RESIDUAL VOLUME THE WMD WAS -28.62 ML. BETA-SITOSTEROL DID NOT REDUCE PROSTATE SIZE. THE TRIAL USING PURE BETA-SITOSTEROL-BDTA-D-GLUCOSIDE (WA184) SHOWED NO IMPROVEMENT IN URINART FLOW MEASURES. WITHDROWAL RATES FOR MEN ASSIGNED TO BETA-SITOSTEROL AND PLACEBO WERE 7.8% AND 8.0% (NOT SIGNIFICANT), RESPECTIVELY. BETA-SITOSTEROL IMPROVES UROLOGICAL SYMPTOMS AND FLOW MEASURES. HOWEVER, THE EXISTING STUDIES ARE LIMITED BY SHORT TREATMENT DURATION AND LACK OF STANDARDIZED BETA-SITOSTEROL PREPARATIONS. THEIR LONG-TERM EFFECTIVENESS, SAFETY AND ABILITY TO PREVENT THE COMPLICATIONS OF BPH ARE UNKNOWN. |
| Dose amount | VAR |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Gender | MALE |